Barclays Maintains Overweight on Ascendis Pharma, Raises Price Target to $345
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $342 to $345.
Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $342 to $345.